EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 9 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-05-03: Reporting owner WIDDER KENNETH J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-03: Reporting owner RHOADS ANN D; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-03: Reporting owner Hill Malcolm R; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-05-03: Reporting owner GLENN SCOTT L; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-05-03 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-05-03 | RHOADS ANN D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +36,500 36,500 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-05-03 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,500 31,500 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-05-03 | GLENN SCOTT L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-05-03 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-05-03 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,500 37,500 owned after | $2.72 exercise price | 2017-05-05 | |
| 2017-01-25 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $2.36 exercise price | 2017-01-27 | |
| 2017-01-25 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $2.36 exercise price | 2017-01-27 | |
| 2017-01-25 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $2.36 exercise price | 2017-01-27 |